Kephera SBIR Phase 2: Development of POC and ELISA assays to detect and differentiate Herpes Simplex Virus 1 and 2 (75N93024C00045).
Past New Requirement Updated
- Agency
-
National Institutes of Health
Department of Health and Human Services
- Solicitation expected
- Estimated value
- $1,500,000 to $3,000,000
- Set-aside
- Total Small Business
Forecast facts
- Anticipated award
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Points of contact
Forecast details come from HHS's procurement forecast. Agencies' dates and values are estimates.
About this forecast
The National Institutes of Health (NIH) forecasts a new requirement under SBIR Phase 2 contract 75N93024C00045, the Kephera effort to develop point-of-care (POC) and ELISA assays that detect and differentiate Herpes Simplex Virus 1 and 2, with an estimated solicitation release date of 2026-09-01 and an estimated award date of 2026-10-01. The work continues product development of early-stage research that NIH describes as successfully completed, targeting a rapid, inexpensive diagnostic with high sensitivity and specificity to distinguish type 1 and type 2 infections. The source states that existing tests have insufficient sensitivity and specificity and that the western blot standard is too costly and time-consuming for widespread use. The forecast is set aside for Total Small Business and classified under NAICS 541715, Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology).
The estimated award value range is $1.5 million to $3 million. The source does not provide quantities, a period of performance, or a place of performance. Points of contact are Callie Prassinos, Contracting Officer at NIH (callie.prassinos@nih.gov, +1 240-669-5155), and Jonathan Glock, National Institutes of Health (jglock@niaid.nih.gov).
Forecast text
An application to continue the product development of this successfully completed early-stage research for a diagnostic to detect Herpes Simplex Virus and differentiate between type 1 and type 2 infections in people. Existing tests have insufficient sensitivity and specificity, while the western blot assay, the current standard, is too costly and time consuming for widespread use. A rapid, inexpensive test that can detect and distinguish type1 and type 2 infections with high sensitivity and specificity is needed to improve medical care and public health surveillance of these infections.
On GovTribe
Work this forecast
- Track it in your pipeline
- Find teaming partners
- Similar forecasts
- Ask GovTribe AI about this forecast